HC Wainwright & Co. Maintains Buy on MEI Pharma, Lowers Price Target to $5
HC Wainwright & Co. analyst Andrew Fein maintains MEI Pharma (NASDAQ:MEIP) with a Buy and lowers the price target from $10 to $5.
Stifel Downgrades MEI Pharma to Hold, Lowers Price Target to $2
Stifel analyst Stephen Willey downgrades MEI Pharma (NASDAQ:MEIP) from Buy to Hold and lowers the price target from $6 to $2.
MEI Pharma’s Return On Capital Employed Insights
According to data from Benzinga Pro, during Q2, MEI Pharma's (NASDAQ:MEIP) reported sales totaled $18.22 million. Despite a 51.46% increase in earnings, the company posted a loss of $5.77 million.
Recap: MEI Pharma Q2 Earnings
MEI Pharma (NASDAQ:MEIP) reported its Q2 earnings results on Thursday, February 10, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
MEI Pharma beat estimated earnings by 55.0%, reporting an EPS of $-0.09 versus an estimate of $-0.2.
Jefferies Initiates Coverage On MEI Pharma with Buy Rating, Announces Price Target of $4
Jefferies analyst Chris Howerton initiates coverage on MEI Pharma (NASDAQ:MEIP) with a Buy rating and announces Price Target of $4.
MEI Pharma Raises $45M Via Equity Issued At 14% Discount
MEI Pharma Inc (NASDAQ:MEIP) priced the underwritten public offering of 17.5 million shares at $2.60/share for gross proceeds of $45.5 million.…